

0040-4020(94)00373-4

3'-C-Phosphonates as Nucleotides Analogues Synthesis Starting from Original C-Phosphonosugars (in ribo- and deoxyribo- series)

Corine SERRA, Georges DEWYNTER, Jean-Louis MONTERO* and Jean-Louis IMBACH

Laboratoire de Chimie Bio-organique (UA 488 CNRS), cc 073
Université de Montpellier II- Sciences et techniques du Languedoc-
place E. Bataillon 34 095 Montpellier cedex 5 . FRANCE

dedicated to Pr Leroy B. Townsend for his 60th birthday.

Key words: 3-C-phosphonosugar, 3'-C-phosphonucleoside, Pudovic reaction, α -hydroxyphosphonate

Abstract: 3-C-phosphonosugars were synthesised starting from 2-deoxy-D-ribose and α -D-xylofuranose via the Pudovic reaction followed by reduction. Their condensation with nucleobases (thymine and adenine) gave original 3'-C-phosphonucleosides in ribo- and 2-deoxyribo- series, with a stereocontrol of the reactions.

Phosphate esters are ubiquitous compounds in biological systems. Chemists and biologists have identified them as prototypes for the design and synthesis of analogues in order to study biological processes and to prepare drugs.

The replacement of the O-phosphate group in a biologically active molecule by a phosphonic acid group^{1,2} might be expected to have interesting biological effects, because these compounds are structurally similar to phosphate compounds and are highly stable. The C-P bond which replaces the C-O-P bond cannot be hydrolysed by phosphatases.


Nucleosides analogues are important as potential antimetabolites. Formation of their active triphosphate derivatives, which subsequently enter the natural nucleotide pool, requires a free 5'-OH. Therefore, most chemical modifications of the sugar moiety have involved the other positions. Among them a number of 3'-substituted nucleosides have been synthesized, for example AZT and ddI, currently used for anti-HIV chemotherapy.

We have been interested in the synthesis of phosphonate analogues of 3'-nucleotides (Structure I, Figure 1). In addition to their antimetabolitic potential, such compounds might be useful as new synthons for the elaboration of antisense modified oligonucleotides for antiviral or antitumoral chemotherapy.

Several approaches to the synthesis of isosteric (Figure 1, Structures II and IV) and non-isosteric phosphonates (Figure 1, Structure III) analogues of nucleotides have been reported³. Methods involving a stabilised Wittig reagent or the Arbuzov reaction with an halogen derivative have most often been employed. But these routes are not applicable to structure I (Figure 1). Therefore we have developed an alternative

synthesis via the Pudovic reaction ⁴⁻⁶ which gives the corresponding α -hydroxyphosphonate. This paper describes the synthesis of 3'-deoxy-3'-phosphononucleosides of thymine and adenine in the DNA and RNA series (Structure I with B = thymine or adenine, X = H or OH) by condensation of the appropriate phosphonosugar and the aglycon. This approach is of considerable interest because it is general, starting from a phosphonosugar precursor it is possible to obtain numerous phosphononucleosides by condensation with natural or modified bases.

- Figure 1: Phosphonates Analogues of Nucleotides-




SYNTHESIS:

Starting from 2-deoxy-D-ribose, we have developed a route to 3'-phosphono-2'-deoxyribonucleosides. Alternatively, starting from 1,2-isopropylidene- α -D-xylofuranose, the ribonucleosides can be obtained and subsequently transformed into 2'-deoxyribonucleosides ⁷.

2-Deoxy-D-ribose was cyclized by the C.C. Bhat procedure⁸ and then selectively protected using the Mitsunobu reaction⁹ to give compound 2 (mixture α/β , proportions 42/58) with an overall yield of 72%. Condensation of a 2-deoxy-sugar with a nucleobase generally gives an anomeric mixture of nucleosides, therefore we have not separated the 2 α and 2 β anomers. Compound 5 was obtained in 90% yield from commercially available 1,2-isopropylidene- α -D-xylofuranose. Moffatt oxidation¹⁰ of 2 and 5 afforded the ketosugars 3 and 6, respectively, in quantitative yield (Scheme 1).


- Scheme 1 -



(DEAD: diethylazodicarboxylate)


EDC: N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride)

Conversion of 3 and 6 to the corresponding α -hydroxyphosphonates (7 and 8) by means of the Pudovic reaction⁵ (Scheme 2) occurred in a stereocontrolled manner. The 3 α and 3 β anomers gave respectively 7 α and 7 β which were separated. Stereocontrol presumably results in part from the presence of the anomeric OCH₃ groups, the reagent approaching from opposite side of the OCH₃, since it is reasonable to assume that the α and β anomers of 3 give rise to compounds 7 α and 7 β with the 3R and 3S configurations respectively. Product 8, on the other hand, was shown to possess only the 3S configuration; the stereoselectivity was due to the adjacent isopropylidene group, which prevents the phosphite from approaching above the plane of the sugar. Products 7 α , 7 β and 8 were obtained in 19%, 37% and 95% yields, respectively. D.F. Wiemer and coworkers have described the hydrophosphonylation of nucleotides and observed stereocontrol resulting from the presence of the nucleobase. In these instances the phosphonate group was above the plane of the sugar¹¹.




- Figure 2: Coupling Constants
in the ^1H NMR Spectrum of $\underline{8}$ -

The stereochemistry of $\underline{8}$ was unambiguously established from the ^1H NMR spectrum by the cis coupling between H2 and P (8.8 Hz) and the trans coupling between H4 and P (27.5 Hz) $\underline{6}$. The position of H2 and H4 was known and therefore the observed couplings between H2 and P, and H4 and P confirmed structure $\underline{8}$ (Figure 2) with the phosphonate group above the plane of the sugar.




Reduction of $\underline{7\alpha}$, $\underline{7\beta}$ and $\underline{8}$, using the modification of the Barton reaction developed by Dolan and Mc Millan ¹², produced the deoxygenated products. Epimerization was observed with $\underline{7\alpha}$ and $\underline{7\beta}$, each affording a C3 epimeric mixture, respectively $\underline{9\alpha} + \underline{9'\alpha}$ and $\underline{9\beta} + \underline{9'\beta}$. The epimers could not be separated. The yields were respectively 86 and 60%. However $\underline{8}$ underwent stereoselective deoxygenation, which resulted from the presence of isopropylidene group, giving only $\underline{10}$ with a 3R configuration in 93% yield.



(OxalylCl: monomethyloxalyl chloride; DMAP: dimethylaminopyridine; AIBN: $\alpha\alpha'$ -azobisisobutyronitrile)

- Figure 3: Coupling Constants in the ¹H NMR Spectrum of 10 -

The position of the phosphonate group was established unambiguously from the observed cis coupling between H2 and H3 and trans coupling between H3 and H4: the phosphonate group is located below the plane of the sugar (Figure 3).




Condensation of 9 (mixture of the 4 stereoisomers) with thymine ¹³ led to the phosphononucleoside 11 as a mixture of 4 stereoisomers (60%) (Scheme 4). Separation of the 4 isomers 11 (a, b, c and d) by HPLC gave analytical samples of each compound and the ¹H NMR spectra allowed structure assignments.

Diacetylation of 10 gave the phosphonosugar 12 in 76% yield. The coupling constants observed on its ¹H NMR spectrum confirmed also the position of the phosphonate group. Condensation of 12 with thymine by the Vorbrüggen process ^{14,15} and with adenine by the Saneyoshi process ^{16,17} gave products 13 (29%) and 14

(28%). However, nucleosides **13** and **14** were exclusively the β anomers due to the participation of the acetate group at C2 (Scheme 4).

On the other hand, the reduction of the α -hydroxyphosphonates described by D.F. Wiemer ¹¹ would probably give the corresponding C3 epimeric phosphonates. This seems to be confirmed by the work of Kakefuda who has studied this type of reduction and described an "inversion" on the carbon bearing the hydroxyl ¹⁸.


- Scheme 4 -



(HMDS: hexamethyldisilazane)


Deprotection of **11** (mixture of 4 stereoisomers) under basic conditions ¹⁹ (Scheme 5) gave **15** and **15'** in equal amounts with an overall yield of 50%. Partial degradation of **11** was also observed. Surprisingly, the mixture of 4 stereoisomers (**11**) produced only two isomers **15** and **15'** whose stereochemistry was established by ¹H NMR, indicating inversion in the course of reaction for the two compounds possessing the 3R configuration. This type of inversion has been noted previously with 3'-cyanonucleosides ²⁰. On the other hand, basic deprotection ¹⁵ of **13** and **14** afforded only the corresponding products **16** (75%) and **17** (85%).

- Scheme 5 -




Selective deprotection of the hydroxyl at C2 by the Ishido proceeding ²¹ in compounds 13 and 14 (70 and 67% yields respectively), followed by deoxygenation by the Barton reaction ²²⁻²⁴, resulted in compounds 11b and 20, in 83 and 52% yields, respectively. Basic hydrolysis ¹⁹ then afforded 15 and 21 in 55% yields (Scheme 6).

- Scheme 6 -



Dealkylation of the phosphonate esters 16, 17 and 21 with tribromomethylsilane 25 gave the corresponding phosphonic acids 22, 23, and 24, isolated as hygroscopic monoammonium salts (Scheme 7).

- Scheme 7 -



Compounds 15-17 and 21-24 were screened for anti-HIV activity in two cell lines: MT4 and CEM (tests conducted in the laboratory of Professor Kirn, University of Strasbourg, France). No significant activity was found, although cytotoxicity was observed at concentrations greater than 10^{-5} M. The inhibitory properties of 23 and 24 against adenylate cyclase are currently under investigation.

CONCLUSION:

A direct synthesis of 2',3'-dideoxy-3'-phosphothymidine (15) starting from 2-deoxy-D-ribose has been achieved. However, the overall yield was low due to the instability of some intermediates, as well as the lack of stereochemical selectivity inherent in this route. The use of 1,2-isopropylidene- α -D-xylofuranose as starting material affords exclusively β ribonucleosides with the desired (R) configuration at C3 (phosphonate group below the plane of the sugar). Furthermore, the method is more general in that it may be used to prepare both ribo- and 2'-deoxyribonucleosides with various nucleobases. Work in progress is directed towards the application of the synthesis to other nucleosides and the further functionalization of the 3'-phosphonate group.

EXPERIMENTAL SECTION:

Melting points were determined in open capillary tubes on a Thermotechnal apparatus and are uncorrected. IR spectra were recorded on a Perkin Elmer spectrophotometer. Microanalysis were performed in the microanalysis laboratory of ENSCM (Montpellier). The HPLC analysis and separations were performed with a Waters-Millipore system (C18 Nucleosil column, eluent: $\text{H}_2\text{O} / \text{CH}_3\text{CN}$). Ultra-violet spectra (UV) were recorded on a Cary 1186 spectrophotometer. Proton and carbon nuclear magnetic resonances were determined with a AC 250 Bruker spectrometer. Chemical shifts are expressed in parts per million, with TMS as reference. The multiplicity was indicated as: s (singlet), d (doublet), t (triplet), q (quadruplet), m (multiplet) and l (large). Phosphorus nuclear magnetic resonances were determined with a WP 200 SY Bruker spectrometer, chemical shifts are expressed in parts per million, with phosphoric acid as reference. Fast-atom bombardment mass spectra (FAB-MS) were recorded in the positive or negative ion mode on a JEOL DX 300 mass spectrometer and the matrix were glycerol (G), a mixture of glycerol and thioglycerol (50/50 v/v) (GT) or metanitrobenzyl alcohol (NBA). Optical rotations were measured in a 1 cm cell on a Perkin-Elmer Model 241 spectropolarimeter. Thin layer chromatography (TLC) was performed on a precoated aluminium sheets of silica

gel 60 F₂₅₄ (Merk n° 5554), visualization of products being accomplished by UV absorbance or by charring with 10% ethanolic sulfuric acid and heating. Column chromatography was performed with silica gel 60 (Merk n°9385) under atmospheric pressure. Preparative layer chromatography was performed by plates of silica gel 60 F₂₅₄ (Merk n° 13895) (PLC). All the solvents used for the reactions were anhydrous.

1-O-Methyl-2-deoxy-5-O-benzoyl- α -D-ribofuranose **2**.

2-deoxy-D-ribose **1** (10 g, 74.4 mmol) in MeOH (180 ml) was treated with MeOH saturated with HCl (1 mL) at room temperature. After 15 min of stirring the reaction mixture was neutralised with Ag₂CO₃, filtered through celite, concentrated under vacuum and coevaporated with toluene.

The resulting oil was dissolved in THF (20 ml), then PPh₃ (19.5 g, 81.8 mmol), benzoic acid (9 g, 81.8 mmol) and DEAD (11.5 ml, 81.8 mmol) were added successively. After stirring for 2 days at room temperature, the mixture was concentrated. The residue was purified by column chromatography over silica gel, eluted with AcOEt / hexane (gradient 30/70 to 40/60) and gave **2** (12.2 g, 72%) as an oil.

R_f = 0.7 (AcOEt)

MS m/z (FAB > 0, NBA): 253 (M+H)⁺, 275 (M+Na)⁺, 221 (M-OCH₃)⁺, 105 (PhCO)⁺, 441 (M-OCH₃+H)⁺

¹H NMR (CDCl₃) δ 2.15 (m, 2H, H₂ and H_{2'}), 3.18 (m, 1H, OH), 3.28 and 3.38 (s and s, 3H, OCH₃, α/β : 42/58), 4-4.6 (m, 4H, H₃, H₄, H₅ and H_{5'}), 5.07 and 5.11 (dd and d, 1H, H₁, α/β : 42/58), 7.4 (m, 2H, arom meta), 7.55 (m, 1H, arom para), 8 (m, 2H, arom ortho)

1-O-Methyl-2-deoxy-5-O-benzoyl- α -D-furan-3-ulose **3**.

The sugar **2** (10 g, 39.7 mmol) was dissolved in DMSO (75 ml) and benzene (75 ml), EDC (14.4 g, 79.4 mmol) was added followed by dichloroacetic acid (1.6 ml, 19.8 mmol) with stirring at room temperature. After 3 hours the reaction was complete. The reaction mixture was diluted with CH₂Cl₂ and washed successively with brine and water, dried over Na₂SO₄ and concentrated. The oil obtained was used for the next step without further purification because of its instability on silica gel.

IR: 1765 cm⁻¹

1,2-Isopropylidene-5-O-benzoyl- α -D-xylofuranose **5**.

In a solution of 1,2-isopropylidene- α -D-xylofuranose (10g, 52.6 mmol) in pyridine (230 ml) was added BzCl (6.1 ml, 52.6 mmol) at 0°C. After stirring for 1 hour, the solution was concentrated and coevaporated with toluene. The crude product was dissolved in AcOEt and the organic phase was washed with H₂O, saturated aqueous NaHCO₃, H₂O and dried over Na₂SO₄. The oil was purified by column chromatography over silica gel eluted with CH₂Cl₂ / MeOH 98/2. The product was precipitated in a mixture of AcOEt and hexane to give a white solid (14 g, 91%).

mp 85°C

R_f = 0.74 (AcOEt)

MS m/z (FAB > 0, GT): 295 (M+H)⁺, 237 (M-C₃H₆O+H)⁺

¹H NMR (CDCl₃) δ 1.4 (s, 3H, CH₃), 1.6 (s, 3H, CH₃), 3.4 (d, 1H, OH, J_{OH-H3}=4Hz), 4.25 (m, 1H, H₃), 4.4 (m, 2H, H₅ and H₄), 4.65 (d, 1H, H₂, J_{H1-H2}=3.63Hz), 4.8 (dd, 1H, H_{5'}, J_{H5-H5'}=12.7Hz and J_{H5'-H4}=9.19Hz), 6.1 (d, 1H, H₁, J_{H1-H2}=3.63Hz), 7.5 (m, 2H, arom meta), 7.65 (m, 1H, arom para), 8.15 (m, 2H, arom ortho)

1,2-Isopropylidene-5-O-benzoyl- α -D-furanos-3-ulose **6**.

The ketone **6** was prepared according to the same procedure as **3** with the 5-O-benzoyl-1,2-isopropylidene- α -D-xylofuranose **5** (14 g, 47.6 mmol) in DMSO (100 ml) and benzene (100 ml) with EDC (12.7 g, 66.6 mmol) and dichloroacetic acid (2 ml, 23.8 mmol). The yield of white solid **6** was 87% (12 g).

m.p. 85 °C (Et₂O)

MS m/z (FAB > 0, GT): 293 (M+H)⁺, 235 (M-C₃H₆O+H)⁺

^1H NMR (CDCl_3) δ 1.45 (s, 3H, CH_3), 1.55 (s, 3H, CH_3), 4.45 (d and dd, 2H, H2 and H5, $J_{\text{H1-H2}}=4.37\text{Hz}$, $J_{\text{H5-H5'}}=11.7\text{Hz}$ and $J_{\text{H5-H4}}=4.3\text{ Hz}$), 4.7 (m, 2H, H5' and H4), 6.15 (d, 1H, H1, $J_{\text{H1-H2}}=4.37\text{Hz}$), 7.45 (m, 2H, arom meta), 7.6 (m, 1H, arom para), 8 (m, 2H, arom ortho)

Analysis: cal. for $\text{C}_{15}\text{H}_{16}\text{O}_6$: C 61.64, H 5.48; found: C 61.70, H 5.83%

1-O-Methyl-2-deoxy-3-(R)-C-dimethylphosphono-5-O-benzoyl- α -D-furanose 7 α and 1-O-methyl-2-deoxy-3-(S)-C-dimethylphosphono-5-O-benzoyl- β -D-furanose 7 β .

The ketosugar 3 (39.7 mmoles) was dissolved in dimethyl phosphite (50 ml) and NEt_3 (5.4 ml, 39.7 mmoles) was added at room temperature. After stirring 4 hours the crude product was concentrated under vacuum. The resulting oil was dissolved in AcOEt and washed with saturated aqueous NaHCO_3 and with H_2O . The organic phase was dried over Na_2SO_4 and concentrated under vacuum. Purification by column chromatography over silica gel eluted with AcOEt afforded an anomeric mixture 7 α +7 β . The anomers were separated by the crystallization of 7 α in Et_2O : 7 α (2.7 g, 19%), 7 β (5.3 g, 37%).

7 α : m.p. 121-122°C (Et_2O)

Rf = 0.3 (AcOEt)

0.6 (CH_2Cl_2 / MeOH, 93/7)

MS m/z (FAB > 0, NBA): 361 (M+H)⁺, 329 (M-OCH₃)⁺, 105 (PhCO)⁺, 720 (2M)⁺

^{31}P NMR (CDCl_3) δ 23.4

^1H NMR (CDCl_3) δ 2.3 (d, 1H, H2), 2.6 (m, 1H, H2'), 3.35 (s, 3H, anomeric OCH₃), 3.7 (d, 1H, OH, $J_{\text{HP}}=25.3\text{ Hz}$), 3.85 (2d, 6H, $\text{P}(\text{OCH}_3)_2$, $J_{\text{HP}}=10.5\text{Hz}$), 4.55 (m, 1H, H4), 4.7 (m, 2H, H5 and H5'), 5.10 (dd, 1H, H1, $J_{\text{H1-H2}}=1.12$ and $J_{\text{H1-H2'}}=4.6\text{Hz}$), 7.45 (m, 2H, arom meta), 7.55 (m, 1H, arom para), 8.1 (m, 2H, arom ortho)

Analysis: cal. for $\text{C}_{15}\text{H}_{21}\text{O}_7\text{P}$: C 50.00, H 5.83; found: C 49.90, H 5.63%

7 β : Rf = 0.3 (AcOEt)

Rf = 0.5 (CH_2Cl_2 / MeOH, 93/7)

^{31}P NMR (CDCl_3) δ 22.7

^1H NMR (CDCl_3) δ 2.2 (m, 1H, H2), 2.6 (m, 1H, H2'), 3.4 (s, 3H, anomeric OCH₃), 3.8 (m, 6H, $\text{P}(\text{OCH}_3)_2$), 3.95 (d, 1H, OH, $J_{\text{HP}}=25\text{Hz}$), 4.4 (m, 1H, H4), 4.65 (m, 2H, H5 and H5'), 5.15 (d, 1H, H1, $J=5.3\text{Hz}$), 7.45 (m, 2H, arom meta), 7.55 (m, 1H, arom para), 8.1 (m, 2H, arom ortho)

Analysis: cal. for $\text{C}_{15}\text{H}_{21}\text{O}_7\text{P}$: C 50.00, H 5.83; found: C 49.60, H 5.65%

1,2-Isopropylidene-3-C-dimethylphosphono-5-O-benzoyl- α -D-ribofuranose 8.

The synthesis of 8 starting from 6 (10 g, 34.2 mmoles) was carried out by the same reaction and work up procedure used for 7. The residue was purified by column chromatography over silica gel eluted with CH_2Cl_2 / MeOH (100/0 and 99/1) to give 8 (13.1 g, 95%) as a white solid.

m.p. 58 °C

Rf = 0.25 (CH_2Cl_2 / MeOH, 97/3)

$[\alpha]_{\text{D}}^{20} = +5.7$ (c=1.4, CHCl_3)

MS m/z (FAB > 0, NBA): 403 (M+H)⁺, 425 (M+Na)⁺, 345 (M-C₃H₆O+H)⁺, 805 (2M+H)⁺

^{31}P NMR (CDCl_3) δ 21.85

^1H NMR (CDCl_3) δ 1.4 (s, 3H, CH_3), 1.6 (s, 3H, CH_3), 3.3 (d, 1H, OH, $J_{\text{H-P}}=20.9\text{ Hz}$), 3.88 (d, 3H, POCH_3 , $J_{\text{H-P}}=10.6\text{Hz}$), 3.89 (d, 3H, POCH_3 , $J_{\text{H-P}}=10.6\text{Hz}$), 4.3 (ddd, 1H, H4, $J_{\text{H4-P}}=27.5\text{Hz}$, $J_{\text{H4-H5}}=8.8\text{ Hz}$ and $J_{\text{H4-H5'}}=2.78\text{Hz}$), 4.6 (dd, 1H, H5, $J_{\text{H5-H4}}=8.8\text{Hz}$ and $J_{\text{H5-H5'}}=12\text{Hz}$), 4.85 (dd, 1H,

H5', J_{H5'-H4}=2.8Hz and J_{H5-H5}=12Hz), 4.78 (dd, 1H, H2, J_{H1-H2}=3.9Hz and J_{H2-P}=8.8Hz), 5.95 (d, 1H, H1, J_{H1-H2}=3.9Hz), 7.4 (m, 2H, arom meta), 7.6 (m, 1H, arom para), 8.1 (m, 2H, arom ortho)

Analysis: cal. for C₁₇H₂₃O₉P: C 50.75, H 5.72; found: C 50.56, H 5.86%

Epimeric mixture of 1-O-methyl-2,3-dideoxy-3-(R and S)-C-dimethylphosphono-5-O-benzoyl- α -D-furanoses 9 α and 9 α' .

The alcohol 7 α (2.2 g, 6.1 mmoles) was dissolved in CH₃CN (40 ml) and 4-(DMAP) (3.74 g, 30.5 mmoles) was added, followed by monomethyloxalyl chloride (2.9 ml, 30.5 mmoles) by drops at 10°C. After 5 mn of stirring the reaction mixture was poured onto H₂O and AcOEt. The aqueous phase was extracted with AcOEt. The combined organic phases were washed with saturated aqueous NaHCO₃ and H₂O, dried over Na₂SO₄ and concentrated under vacuum. The oil was coevaporated with toluene and dissolved in the same solvent (30 ml), Bu₃SnH (2.4 ml, 9.1 mmoles) was added followed by AIBN (220 mg) under an argon atmosphere. The mixture was stirred at 100°C for 2 hours and then concentrated. The residue was purified by column chromatography over silica gel (eluent: gradient of MeOH 0% to 2% in CH₂Cl₂) to give 9 α + 9 α' (1.8 g, 86%).

R_f = 0.3 (AcOEt)

MS m/z (FAB > 0, NBA): 345 (M+H)⁺, 313 (M-OCH₃)⁺, 105 (PhCO)⁺

³¹P NMR (CDCl₃) δ 28.85 and 32.01

¹H NMR (CDCl₃) δ 2.6 (m, 1H, H2), 2.9 (m, 1H, H2'), 3.15 (m, 1H, H3), 3.65 and 3.70 (s and s, 3H, anomeric OCH₃, 50/50), 4.15 (m, 6H, P(OCH₃)₂), 4.9 (m, 3H, H4, H5 and H5'), 5.4 and 5.5 (m and m, 1H, H1, 50/50), 7.8 (m, 2H, arom meta), 7.9 (m, 1H, arom para), 8.45 (m, 2H, arom ortho)

Analysis: cal. for C₁₅H₂₁O₇P: C 52.32, H 6.10; found: C 52.04, H 6.15%

Epimeric mixture of 1-O-methyl-2,3-dideoxy-3-(R and S)-C-dimethylphosphono-5-O-benzoyl- β -D-furanoses 9 β and 9 β' .

The synthesis of 9 β was carried out by the same reaction and work up procedure used for 9 α starting from 7 β (5.15 g, 14 mmoles). The mixture of the sugars 9 β and 9 β' was obtained as a yield of 60% (2.85 g).

R_f = 0.30 (AcOEt)

MS m/z (FAB > 0, NBA): 313 (M-OCH₃)⁺, 105 (PhCO)⁺

³¹P NMR (CDCl₃) δ 30.63 and 30.78

¹H NMR (CDCl₃) δ 2.6 (m, 1H, H2), 2.8 (m, 1H, H2'), 3.1 (m, 1H, H3), 3.3 (2s, 3H, anomeric OCH₃, 55/45), 4.1 (m, 6H, P(OCH₃)₂), 5 (m, 3H, H4, H5 and H5'), 5.3 (m, 1H, H1), 7.8 (m, 2H, arom meta), 7.9 (m, 1H, arom para), 8.4 (m, 2H, arom ortho)

1,2-Isopropylidene-3-deoxy-3-C-dimethylphosphono-5-O-benzoyl- α -D-ribofuranose 10.

The synthesis of 10 was carried out by the same reaction and work up procedure used for 9 starting from 8 (13g, 32.3 mmoles). In this reaction only 1.5 equivalents of 4-(DMAP) and monomethyloxalyl chloride was employed. The sugar 10 was obtained with a yield of 93% (11.7g).

R_f = 0.35 (CH₂Cl₂ / MeOH, 97/3)

[α]_D²⁰ = +53.6 (c=1.4, CHCl₃)

MS m/z (FAB > 0, NBA): 387 (M+H)⁺, 329 (M-C₃H₆O+H)⁺, 105 (PhCO)⁺

³¹P NMR (CDCl₃) δ 25.06

¹H NMR (CDCl₃) δ 1.35 (s, 3H, CH₃), 1.6 (s, 3H, CH₃), 3.7 (d, 3H, POCH₃, J_{H-P}=11Hz), 3.85 (d, 3H, POCH₃, J_{H-P}=11Hz), 2.6 (ddd, 1H, H3, J_{H3-P}=19.1Hz, J_{H3-H4}=10.7Hz, J_{H3-H2}=4.6Hz), 4.35 (dd, 1H, H5, J_{H5-H4}=4.5Hz and J_{H5-H5}=12.3Hz), 4.6 (ddd, 1H, H4, J_{H5-H4}=4.5Hz, J_{H5'-H4}=1.8Hz, J_{H3-}

H₄=10.7Hz), 4.7 (dd, 1H, H^{5'}, J_{H^{5'}-H⁵}=12.5Hz), 4.98 (d, 1H, H₂, J_{H₁-H₂}=4.16Hz), 5.88 (d, 1H, H₁, J_{H₁-H₂}=3.67Hz), 7.45 (m, 2H, arom meta), 7.6 (m, 1H, arom para), 8 (m, 2H, arom ortho)
 Analysis: cal. for C₁₇H₂₃O₈P: C 52.85, H 5.96; found: C 52.38, H 6.07%

N1-(2,3-dideoxy-3-C-dimethylphosphono-5-O-benzoyl-furanosyl)-thymine 11.

A suspension of thymine (700 mg) and a catalytic amount of ammonium sulfate in HMDS (30 ml) was heated under reflux for 24 hours. After cooling, the excess of HMDS was removed under vacuum. The resulting silylated thymine was dissolved in CH₃CN (2 ml), then a solution of sugar **9** (mixture of the 4 stereoisomers) (1 g, 2.9 mmoles) and SnCl₄ (0.7 ml, 5.8 mmoles) were added successively. The reaction mixture was heated under reflux for 15 mn, cooled and neutralised with saturated aqueous NaHCO₃. The solution was filtered through celite, and the product was extracted with AcOEt. The organic phases were dried under Na₂SO₄ and concentrated under vacuum. Chromatography of the residue on a silica gel column (eluent: CH₂Cl₂ and CH₂Cl₂ / MeOH 97/3) led the isolation of **11** as a mixture of 4 stereoisomeric compounds (1RS, 3RS) as a foam (760 mg, 60%). A separation by HPLC yield an analytical sample of each isomer.

Mixture of the 4 isomers.

R_f = 0.35 (CH₂Cl₂ / MeOH, 93/7)

MS m/z (FAB > 0, NBA): 439 (M+H)⁺, 313 (M-Base)⁺

N1-(2,3-dideoxy-3-(S)-C-dimethylphosphono-5-O-benzoyl-α-D-ribofuranosyl)-thymine 11a.

¹H NMR (CDCl₃) δ 1.75 (d, 3H, CH₃, J_{H₅-H₆}=0.7Hz), 2.25 (m, 1H, H_{2'}), 2.75 (m, 1H, H_{3'}), 2.95 (m, 1H, H_{2''}), 3.8 (2d, 6H, P(OCH₃)₂, J_{H-P}=10Hz), 4.65 (m, 3H, H_{4'}, H_{5''} and H_{5'''}), 6.14 (dd, 1H, H_{1'}, J_{H_{1'}-H_{2'}}= 6 and J_{H_{1'}-H_{2''}}= 7.9 Hz), 7.5 (m, 4H, 3H arom and H₆), 8.05 (m, 2H, arom ortho), 8.9 (sl, 1H, NH)
³¹P NMR (CDCl₃) δ 29.96

N1-(2,3-dideoxy-3-(S)-C-dimethylphosphono-5-O-benzoyl-β-D-ribofuranosyl)-thymine 11b.

¹H NMR (CDCl₃) δ 1.6 (d, 3H, CH₃ en 5, J_{H₅-H₆}=1Hz), 2.4 (m, 1H, H_{2'}), 2.8 (m, 2H, H_{2''} and H_{3'}), 3.85 (d, 6H, P(OCH₃)₂, J_{H-P}=10.8Hz), 4.6 (m, 2H, H_{4'} and H_{5'}), 4.85 (dd, 1H, H_{5''}, J_{H_{5''}-H_{5'''}}=13.2Hz and J_{H_{5''}-H_{4'}}=2.9Hz), 6.1 (dd, 1H, H_{1'}, J_{H_{1'}-H_{2'}}=6.7Hz and J_{H_{1'}-H_{2''}}=4Hz), 7.25 (d, 1H, H₆, J_{H₅-H₆}=1.08Hz), 7.45 (m, 2H, arom meta), 7.6 (m, 1H, arom para), 8.05 (m, 2H, arom ortho), 8.6 (sl, 1H, NH)
³¹P NMR (CDCl₃) δ 29.1

N1-(2,3-dideoxy-3-(R)-C-dimethylphosphono-5-O-benzoyl-α-D-ribofuranosyl)-thymine 11c.

¹H NMR (CDCl₃) δ 1.93 (d, 3H, CH₃, J_{H₅-H₆}=1Hz), 2.5 (m, 1H, H_{2'}), 2.85 (m, 2H, H_{2''} and H_{3'}), 3.75 (2d, 6H, P(OCH₃)₂, J_{H-P}=10.9Hz), 4.6 (m, 2H, H_{4'} and H_{5'}), 4.9 (m, 1H, H_{5''}), 6.11 (dd, 1H, H_{1'}, J_{H_{1'}-H_{2'}}= 2.3 and J_{H_{1'}-H_{2''}}= 6.3 Hz), 7.1 (d, 1H, H₆, J_{H₆-H₅}= 1.1Hz), 7.5 (m, 2H, arom meta), 7.6 (m, 1H, arom para), 8.1 (m, 2H, arom ortho), 8.9 (sl, 1H, NH)
³¹P NMR (CDCl₃) δ 27.56

N1-(2,3-dideoxy-3-(R)-C-dimethylphosphono-5-O-benzoyl-β-D-ribofuranosyl)-thymine 11d.

¹H NMR (CDCl₃) δ 2 (d, 3H, CH₃, J_{H₅-H₆}=0.7Hz), 2.3 (m, 1H, H_{2'}), 2.8 (m, 2H, H_{2''} and H_{3'}), 3.8 (2d, 6H, P(OCH₃)₂, J_{H-P}=10.8Hz), 4.4 (dd, 1H, H_{5'}, J_{H_{4'}-H_{5'}}=4.6Hz and J_{H_{5'}-H_{5''}}=12Hz), 4.6 (dd, 1H, H_{5''}, J_{H_{4'}-H_{5''}}=2.6Hz and J_{H_{5''}-H_{5'''}}=12Hz), 4.75 (m, 1H, H_{4'}), 6.3 (t, 1H, H_{1'}, J_{H₁-H_{2'}}= J_{H₁-H_{2''}}=6.4Hz), 7.35 (d, 1H, H₆, J_{H₆-H₅}= 1.1Hz), 7.45 (m, 2H, arom meta), 7.6 (m, 1H, arom para), 8.05 (m, 2H, arom ortho), 8.5 (sl, 1H, NH)
³¹P NMR (CDCl₃) δ 27.93

1,2-Di-O-acetyl-3-deoxy-3-C-dimethylphosphono-5-O-benzoyl- α -D-ribofuranose 12.

A solution of 10 (13 g, 33.7 mmol) in 85% aqueous acetic acid (36 ml) was heated at 50°C and concentrated H₂SO₄ (1 ml) was added. After 5 hours the reaction mixture was concentrated and pyridine (7.6 ml, 67.4 mmol) was added followed by acetic anhydride (61 ml). After stirring at 50°C for 30 min the reaction was complete and the mixture was concentrated under vacuum. The resulting oil was dissolved in AcOEt and the organic phase was washed with saturated aqueous NaHCO₃ and H₂O, dried over Na₂SO₄ and concentrated. Purification by chromatography over silica gel (eluent CH₂Cl₂/ MeOH 97/3) gave 12 (11 g, 76%).

R_f = 0.35 (CH₂Cl₂ / MeOH, 97/3)

[α]_D²⁰ = -10 (c=1, CHCl₃)

MS m/z (FAB > 0, NBA): 431 (M+H)⁺, 371 (M-OAc)⁺, 329 (M-2 OAc)⁺, 105 (PhCO)⁺

³¹P NMR (CDCl₃) δ 24.64

¹H NMR (CDCl₃) δ 1.85 (s, 3H, OAc), 2.15 (s, 3H, OAc), 3.05 (ddd, 1H, H₃, J_{H₃-P}=14.7Hz, J_{H₃-H₄}=10.2Hz, J_{H₃-H₂}=4.7Hz), 3.75 (t, 6H, P(OCH₃)₂, J_{H-P}=10.8Hz), 4.3 (dd, 1H, H₅, J_{H₅-H₄}=4.4Hz and J_{H₅-H_{5'}}=12.3Hz), 4.75 (dd, 1H, H_{5'}, J_{H₅-H_{5'}}=12.3Hz and J_{H₄-H_{5'}}=2.4Hz), 4.85 (m, 1H, H₄), 5.5 (d, 1H, H₂, J_{H₂-H₃}=4.6Hz), 6.1 (d, 1H, H₁, J_{H₁-P}=2Hz), 7.4 (m, 2H, arom meta), 7.5 (m, 1H, arom para), 8.1 (m, 2H, arom ortho)

Analysis: cal. for C₁₈H₂₃O₁₀P: C 50.23, H 5.35; found: C 50.60, H 5.58%

N1-(2-O-acetyl-3-deoxy-3-C-dimethylphosphono-5-O-benzoyl- β -D-ribofuranosyl)-thymine 13.

To a mixture of 12 (2.7 g, 6.3 mmol) and thymine (790 mg, 6.3 mmol) in CH₃CN (20 ml) were added HMDS (0.96 ml, 5 mmol), TMSCl (0.63 ml, 5 mmol) and SnCl₄ (0.9 ml, 7.6 mmol). The solution was refluxed for 30 min, cooled, neutralised quickly with saturated aqueous NaHCO₃ and filtered through celite. The product was extracted with CH₂Cl₂. The organic phases were dried over Na₂SO₄ and concentrated under vacuum. The crude material was purified by silica gel column chromatography (gradient of methanol 0 to 2% in CH₂Cl₂) to give 13 as a foam (900 mg, 29%).

R_f = 0.35 (CH₂Cl₂ / MeOH, 93/7)

[α]_D²⁰ = -7 (c=1, CHCl₃)

MS m/z (FAB > 0, NBA): 497 (M+H)⁺, 371 (M-base+H)⁺, 437 (M-OAc)⁺

³¹P NMR (CDCl₃) δ 23.9

¹H NMR (CDCl₃) δ 1.65 (d, 3H, CH₃, J_{H₆-H₅}=1Hz), 2.15 (s, 3H, OAc), 3.3 (m, 1H, H_{3'}), 3.75 (d, 3H, POCH₃, J_{H-P}=11.09Hz), 3.8 (d, 3H, POCH₃, J_{H-P}=11.03Hz), 4.45 (dd, 1H, H_{5'}, J_{H_{5'}-H_{4'}}=4.41Hz and J_{H_{5'}-H_{5''}}=12.8Hz), 4.75 (m, 2H, H_{5''} and H_{4'}), 5.7 (m, 2H, H_{1'} and H_{2'}), 7 (d, 1H, H₆, J_{H₅-H₆}=1Hz), 7.5 (m, 2H, arom meta), 7.6 (m, 1H, arom para), 8.05 (m, 2H, arom ortho), 9.7 (sl, 1H, NH)

¹³C NMR (CDCl₃) δ 12.2 (C₅-CH₃), 20.9 (CH₃ acetyl), 40 (d, C_{3'}, J_{C-P}= 150.3Hz), 53.1 (m, P(OCH₃)₂), 63.9 (C_{5'}), 75.8 (d, C_{2'}, J_{C-P}= 6.23 Hz), 78.2 (d, C_{4'}, J_{C-P}= 2.45Hz), 91.6 (d, C_{1'}, J_{C-P}= 8.36Hz), 111.5 (C₅), 128.7 (arom meta), 129.5 (arom ipso), 129.6 (arom ortho), 133.5 (arom para), 136.2 (C₆), 150.0, 163.7, 166.0, 169.8 (4 CO)

Analysis: cal. for C₂₁H₂₅N₂O₁₀P: C 50.80, H 5.04, N 5.64; found: C 50.43, H 5.00, N 5.41%

UV (EtOH 95%): λ _{min} = 228 nm (ϵ =8250), λ _{max} = 262 nm (ϵ =11040); (HCl 1M): λ _{min} = 231 nm, λ _{max} = 265 nm; (KOH 1M): λ _{min} = 224 nm, λ _{max} = 267 nm

N9-(2-O-acetyl-3-deoxy-3-C-dimethylphosphono-5-O-benzoyl- β -D-ribofuranosyl)-adenine 14.

The phosphonosugar 12 (3 g, 7 mmol) was dissolved in CH₃CN (15 ml), adenine (940 mg, 7 mmol) in CH₃CN (10 ml) and SnCl₄ (1.2 ml, 10.5 mmol) were added successively at room temperature. The reaction mixture was stirred for 5 days and concentrated under vacuum. Then it was diluted with AcOEt, washed with saturated aqueous NaHCO₃ and filtered through celite. The organic phase was washed with H₂O,

dried under Na₂SO₄ and evaporated. The resulting crude material was purified by silica gel column chromatography (eluent: CH₂Cl₂ / MeOH 100/0 and 98/2) to give **13** (1g, 28%) as a white foam.

R_f = 0.22 (CH₂Cl₂ / MeOH, 93/7)

[α]_D²⁰ = +5 (c=1, CHCl₃)

MS m/z (FAB > 0, NBA): 506 (M+H)⁺, 371 (M-base+H)⁺, 105 (PhCO)

³¹P NMR (CDCl₃) δ 24.1

¹H NMR (CDCl₃) δ 2.2 (s, 3H, OAc), 3.8 (t, 6H, P(OCH₃)₂, J_{H-P}=11.2Hz), 4.5 (ddd, 1H, H3', J_{H3'-H4'}=10.1Hz, J_{H3'-P}=19.3Hz and J_{H3'-H2'}=5.8Hz), 4.45 (dd, 1H, H5', J_{H5'-H4'}=4.6Hz and J_{H5''-H5'}=12.5Hz), 4.75 (dd, 1H, H5'', J_{H5''-H4'}=2.1Hz and J_{H5''-H5'}=12.5Hz), 4.88 (m, 1H, H4'), 6 (sl, 1H, H1'), 6.2 (m, 1H, H2'), 6.55 (sl, 2H, NH₂), 7.35 (m, 2H, arom meta), 7.5 (m, 1H, arom para), 7.85 (m, 2H, arom ortho), 7.9 (s, 1H, H8), 8.2 (s, 1H, H2)

¹³C NMR (CDCl₃) δ 21.3 (CH₃ acetyl), 39 (d, C3', J_{C-P}= 150Hz), 52-53 (m, P(OCH₃)₂), 63.6 (C5'), 76 (d, C2', J_{C-P}= 5.8Hz), 79 (d, C4', J_{C-P}= 4.3Hz), 90 (d, C1', J_{C-P}= 11Hz), 120.24 (C6), 128.41 (arom meta), 129.42 (arom ipso), 129.71 (arom ortho), 133.29 (arom para), 140.3 (C8), 148.98 (ethylenic C4 or C5), 152.44 (C2), 155.36 (ethylenic C4 or C5), 166.05 and 169.89 (2 CO)

Analysis: cal. for C₂₁H₂₄O₈N₅P: C 50.00, H 4.70, N:13.90; found: C 50.21, H: 4.82, N 13.30%

UV (EtOH 95%): λ_{min} = 233 nm (ε=10400), λ_{max} = 258.5 nm (ε=14000); (HCl 1M): λ_{min} = 238 nm, λ_{max} = 258 nm; (KOH 1M): λ_{min} = 233 nm, λ_{max} = 259 nm

N1-(2,3-dideoxy-3-C-dimethylphosphono-β-D-ribofuranosyl)-thymine 15 and N1-(2,3-dideoxy-3-C-dimethylphosphono-α-D-ribofuranosyl)-thymine 15' (method 1).

The stereoisomeric mixture **11** (40 mg, 0.09 mole) was dissolved in a solution of H₂O and MeOH (2 ml, v/v 1/1), and treated with NEt₃ (0.1 ml). The solution was stirred for 24 hours, and then concentrated under vacuum. Two isomers **15** and **15'** were formed and separated by PLC (eluent: CH₂Cl₂/ MeOH 90/10) with several migrations (yield 50%, proportions 1/1).

NB: The treatment of **10** with methanolic ammonia or MeONa in MeOH gave the same mixture **15** and **15'**.

15 and 15':

R_f = 0.15 (CH₂Cl₂ / MeOH, 93/7)

MS m/z (FAB > 0, NBA): 335 (M+H)⁺

15:

³¹P NMR (CDCl₃) δ 30.1

¹H NMR (CDCl₃) δ 1.8 (d, 3H, CH₃ en 5), 2.3 (m, 1H, H3'), 2.7 (m, 2H, H2' and H2''), 3.7 (2d, 6H, P(OCH₃)₂, J_{H-P}=13Hz and m, 1H, H5'), 4 (dd, 1H, H5'', J_{H5''-H5'}=12Hz, J_{H5''-H4'}=2.6Hz), 4.2 (m, 1H, H4'), 5.95 (q, 1H, H1', J=3.5Hz), 7.55 (d, 1H, H6, J_{H5-H6}=1Hz), 9 (sl, 1H, NH)

15':

³¹P NMR (CDCl₃) δ 30.4

¹H NMR (CDCl₃) δ 1.9 (d, 3H, CH₃, J_{H5-H6}=1Hz), 2.2 (m, 1H, H2'), 2.7 (m, 2H, H2'' and H3'), 3.6 (dd, 1H, H5', J_{H5'-H5''}= 12.2 Hz and J_{H5'-H4'}= 2.9Hz), 3.75 (m, 6H, P(OCH₃)₂), 3.85 (dd, 1H, H5'', J_{H5''-H5'}= 12.2Hz and J_{H5''-H4'}= 3.3Hz), 4.5 (m, 1H, H4'), 6.15 (m, 1H, H1'), 7.1 (d, 1H, H6), 8.1 (sl, 1H, NH)

N1-(3-deoxy-3-C-dimethylphosphono-β-D-ribofuranosyl)-thymine 16.

The phosphononucleoside **13** (380 mg, 0.8 mmole) was treated with a 0.3M solution of MeONa in MeOH (8 ml). After stirring at room temperature for 35 mn, the excess of MeONa was neutralised with dowex 50W2 resin in pyridinium form. The reaction mixture was filtered, the resin was washed with hot MeOH. Then

the solution was concentrated and coevaporated with toluene. Purification by chromatography on a silica gel column eluted with CH₂Cl₂ / MeOH 95/5 gave 16 (200 mg 75%) as a foam.

R_f = 0.14 (CH₂Cl₂ / MeOH, 90/10)

[α]_D²⁰ = +14.5 (c = 1, DMSO)

MS m/z (FAB > 0, NBA): 351 (M+H)⁺, 225 (M-base)⁺, 373 (M+Na)⁺

³¹P NMR (DMSO d₆) δ 28.1

¹H NMR (DMSO d₆) δ 1.7 (s, 3H, CH₃), 2.7 (ddd, 1H, H3'), 3.5 (dl, 1H, H5', J_{H5'-H5''}=10Hz), 3.6 (d, 6H, P(OCH₃)₂, J_{H-P}=11Hz), 3.8 (dl, 1H, H5'', J_{H5'-H5''}=12Hz), 4.3 (m, 2H, H2' and H4'), 5.2 (sl, 1H, OH5'), 5.7 (s, 1H, H1'), 6.2 (d, 1H, OH3', J_{OH-H3'}=5.3Hz), 7.85 (s, 1H, H6), 11.3 (s, 1H, NH)

Analysis: cal. for C₁₂H₁₉N₂O₈P: C 41.14, H 5.43, N 8.00; found: C 41.10, H 5.75, N 7.70%

N9-(3-deoxy-3-C-dimethylphosphono-β-D-ribofuranosyl)-adenine 17.

The synthesis of 17 was carried out by the same reaction and work up procedure used for 16 starting from 14 (280 mg, 0.5 mmole). The nucleoside 17 was obtained as a foam (170 mg, 85%).

R_f = 0.1 (CH₂Cl₂ / MeOH, 93/7)

[α]_D²⁰ = -27.2 (c = 1, DMSO)

MS m/z (FAB > 0, NBA): 360(M+H)⁺, 225 (M-base)⁺, 382 (M+Na)⁺

³¹P NMR (CDCl₃) δ 28.42

¹H NMR (DMSO d₆) δ 3.1 (ddd, 1H, H3'), 3.5 (m, 1H, H5'), 3.7 (2d, 6H, P(OCH₃)₂, J_{H-P}=10.7Hz), 3.8 (m, 1H, H5''), 4.4 (m, 1H, H4'), 4.8 (m, 1H, H2'), 5.25 (t, 1H, OH5', J_{OH-H5'} and J_{OH-H5''}=5.5Hz), 5.95 (sl, 1H, H1'), 6.35 (d, 1H, OH3', J_{OH-H3'}=5.3Hz), 7.3 (sl, 2H, NH₂), 8.1 (s, 1H, H8), 8.4 (s, 1H, H2)

Analysis: cal. for C₁₂H₁₈N₅O₆P: C 40.11, H 5.01, N 19.50; found: C 39.97, H 5.42, N 19.30%

N1-(3-deoxy-3-C-dimethylphosphono-5-O-benzoyl-β-D-ribofuranosyl)-thymine 18.

Hydrazine monohydrate (2.4 mmoles) in solution in acetic acid and pyridine (22 mmoles of NH₂NH₂·H₂O for 66 ml of mixture pyridine-acetic acid, proportions v/v 4/1) was added to 13 (780 mg, 1.6 mmoles). After stirring 24 hours at room temperature, acetone (10 ml) was added, and the stirring was continued for 2 hours. Then the solution was evaporated and partitioned between H₂O and AcOEt. The organic phase was washed with saturated aqueous NaHCO₃ and H₂O, dried over Na₂SO₄ and concentrated. Chromatography on a silica gel column (eluent: gradient of MeOH 2 to 5% in CH₂Cl₂) gave 18 (450 mg, 70%) as a foam.

R_f = 0.23 (CH₂Cl₂ / MeOH, 93/7)

[α]_D²⁰ = +30 (c=1, CDCl₃)

MS m/z (FAB > 0, NBA): 455 (M+H)⁺, 329(M-base+H)⁺, 105 (PhCO)⁺

³¹P NMR (CDCl₃) δ 25.37

¹H NMR (CDCl₃) δ 1.6 (s, 3H, CH₃), 2.75 (ddd, 1H, H3'), 3.7 (d, 3H, POCH₃, J_{H-P}=11.17Hz), 3.85 (d, 3H, POCH₃, J_{H-P}=11.09Hz), 4.5 (dd, 1H, H5', J_{H5'-H4'}=3.67Hz and J_{H5''-H5'}=13.12Hz), 4.7 (sl, 1H, H2'), 4.8 (m, 2H, H5'' and H4'), 5.7 (sl, 2H, H1' and OH), 7.4 (s, 1H, H6), 7.5 (m, 2H, arom meta), 7.6 (m, 1H, arom para), 8 (m, 2H, arom ortho), 10.55 (sl, 1H, NH)

Analysis: cal. for C₁₉H₂₃N₂O₉P: C 50.22, H 5.07, N 6.17; found: C 50.00, H 5.02, N 6.33%

N9-(3-deoxy-3-C-dimethylphosphono-5-O-benzoyl-β-D-ribofuranosyl)-adenine 19.

The synthesis of 19 was carried out by the same reaction and work up procedure used for 18 starting from 14 (850 mg, 1.7 mmoles). The nucleoside 19 was obtained as a foam (520 mg, 67%).

R_f = 0.26 (CH₂Cl₂ / MeOH, 90/10)

[α]_D²⁰ = -7 (c=1, DMSO)

MS *m/z* (FAB > 0, NBA): 464 (M+H)⁺, 329 (M-base+H)⁺, 105 (PhCO)⁺

³¹P NMR (CDCl₃) δ 26.8

¹H NMR (CDCl₃) δ 3.4 (ddd, 1H, H3'), 3.75 (d, 3H, POCH₃, J_{H-P}=11.1Hz), 3.98 (d, 3H, POCH₃, J_{H-P}=11.02Hz), 4.55 (dd, 1H, H5', J_{H5'-H4'}=4.3Hz and J_{H5''-H5'}=12.6Hz), 4.75 (d, 1H, H5'', J_{H5''-H5'}=12.5Hz), 4.95 (m, 1H, H4'), 5.15 (sl, 1H, H2'), 6.05 (s, 1H, H1'), 6.5 (sl, 2H, NH₂), 7.12 (sl, 1H, OH), 7.45 (m, 2H, arom meta), 7.5 (m, 1H, arom para), 7.9 (m, 2H, arom ortho), 8.05 (s, 1H, H8), 8.18 (s, 1H, H2)

Analysis: cal. for C₁₉H₂₂O₇N₅P: C 49.24, H 4.75, N 15.18; found: C 49.10, H 4.61, N 15.00%

N1-(2,3-dideoxy-3-C-dimethylphosphono-5-O-benzoyl-β-D-ribofuranosyl)-thymine 11b (method 2).

To a solution of 18 (400 mg, 0.9 mmole) in CH₂Cl₂ (9 ml) were added phenoxythiocarbonyl chloride (0.25 ml, 1.8 mmoles) and 4-(DMAP) (440 mg, 3.6 mmoles). After stirring 1 hour at room temperature the reaction mixture was diluted with CH₂Cl₂. The organic phase was washed successively with H₂O, 1N aqueous hydrochloric acid, H₂O, saturated aqueous NaHCO₃ and H₂O, then dried over Na₂SO₄ and evaporated to dryness. The residue was coevaporated with toluene and dissolved in the same solvent (22 ml). The solution was treated with Bu₃SnH (0.64 ml, 2.4 mmoles) and AIBN (50 mg, 0.3 mmole) and stirred at 80°C for 1 hour. After evaporation, the crude product was purified by chromatography on a silica gel column with a gradient of MeOH, 0 to 2% in CH₂Cl₂ to give 11b (385 mg, 83%) as a foam.

R_f = 0.35 (CH₂Cl₂ / MeOH, 93/7)

[α]_D²⁰ = 0 (c=1, CHCl₃)

Analysis: cal. for C₁₉H₂₃N₂O₈P: C 52.05, H 5.25, N 6.39; found: C 52.20, H 5.30, N 6.50%

N9-(2,3-dideoxy-3-C-dimethylphosphono-5-O-benzoyl-β-D-ribofuranosyl)-adenine 20.

The synthesis of 20 was carried out by the same reaction and work up procedure used for 11b (method 2) starting from 19 (450 mg, 0.97 mmole). The nucleoside 20 was obtained as a foam (230 mg, 52%).

R_f = 0.47 (CH₂Cl₂ / MeOH, 90/10)

[α]_D²⁰ = 0 (c=1, DMSO)

MS *m/z* (FAB > 0, NBA): 448 (M+H)⁺, 313 (M-base+H)⁺, 105 (PhCO)⁺

³¹P NMR (CDCl₃) δ 29.64

¹H NMR (CDCl₃) δ 2.8 (m, 1H, H2'), 3.1 (m, 1H, H2''), 3.3 (m, 1H, H3'), 3.8 (d, 6H, P(OCH₃)₂, J_{H-P}=10.8Hz), 4.5 (dd, 1H, H5', J_{H5'-H4'}=4.8Hz and J_{H5''-H5'}=12.1Hz), 4.65 (m, 2H, H5'' and H4'), 6.1 (sl, 2H, NH₂), 6.3 (m, 1H, H1'), 7.4 (m, 2H, arom meta), 7.6 (m, 1H, arom para), 7.9 (m, 2H, arom ortho), 8.0 (s, 1H, H8), 8.35 (s, 1H, H2)

Analysis: cal. for C₁₉H₂₂O₆N₅P: C 51.00, H 4.92, N 15.66; found: C 49.80, H 4.72, N 15.51%

N1-(2,3-dideoxy-3-C-dimethylphosphono-β-D-ribofuranosyl)-thymine 15 (method 2).

The phosphononucleoside 11b (synthesised by method 2) (80 mg, 0.18 mmole) was dissolved in a mixture of H₂O and MeOH (proportions v/v 1/1, 4 ml), NEt₃ was added (100 μl) and the reaction mixture was concentrated after 30 mn of stirring. The product was purified by PLC (eluent CH₂Cl₂ / MeOH 90/10) and was obtained as an oil (32 mg, 55%).

R_f = 0.4 (CH₂Cl₂ / MeOH, 90/10)

MS *m/z* (FAB > 0, NBA): 335 (M+H)⁺, 209 (M-base)⁺, 357 (M+Na)⁺, 669 (2M+H)⁺

³¹P NMR (CDCl₃) and ¹H NMR (CDCl₃): see above.

N9-(2,3-dideoxy-3-C-dimethylphosphono-β-D-ribofuranosyl)-adenine 21.

The synthesis of 21 was carried out by the same reaction and work-up procedure used for 22 starting from 20 (100 mg, 0.22 mmole). The nucleoside 21 was obtained as an oil (52 mg, 55%).

R_f = 0.25 (CH₂Cl₂ / MeOH, 90/10)

MS m/z (FAB > 0, NBA): 344 (M+H)⁺, 366 (M+Na)⁺

³¹P NMR (DMSO d₆) δ 31.80

¹H NMR (CDCl₃) δ 2.7 (m, 2H, H₂' and H₃'), 3.1 (m, 1H, H₂"'), 3.5 (m, 2H, H₅' and H₅"'), 3.7 (d, 6H, P(OCH₃)₂, J_{H-P}=10.7Hz), 4.2 (m, 1H, H₄'), 5.2 (sl, 2H, NH₂), 6.3 (q, 1H, H₁', J=3.7Hz), 8.1 (s, 1H, H₈), 8.4 (s, 1H, H₂)

General procedure for the deprotection of the phosphonic acids for 16, 17 and 21.

The phosphononucleosides 16, 17 and 21 were dissolved in CH₃CN (2 ml for 50 mg of nucleoside), a catalytic amount of pyridine was added, then the reaction mixture was treated with BrSiMe₃ (10 equivalents) under an argon atmosphere, and stirred at room temperature for 14 hours. Pyridine (0.5 ml for 50 mg de nucleoside) and water (1 ml for 50 mg) were added. The stirring was continued for 2 hours, and the solution was washed two times with Et₂O and concentrated. The products, as hygroscopic ammonium salts 22, 23 and 24, were obtained as white hygroscopic solids after a purification with PLC (eluent: 2-propanol/ NH₄OH/ H₂O, 7/1/2) and lyophilisation.

N1-(2-hydroxy-3-deoxy-3-C-dihydroxyphosphono-β-D-ribofuranosyl)-thymine (ammonium salt) 22.

R_f = 0.5 (2-propanol / NH₄OH / H₂O, 7/1/2)

MS m/z (FAB < 0, G): 343 (anion+Na⁺), 321 (anion)

³¹P NMR (D₂O) δ 16.80

¹H NMR (D₂O) δ 1.9 (d, 3H, CH₃), 2.6 (m, 1H, H₃'), 3.9 (d, 1H, H₅', J_{H₅'-H₅"}= 12Hz), 4.15 (d, 1H, H₅"', J_{H₅"'-H₅"}= 12.3Hz), 4.6 (m, 2H, H₂' and H₄'), 5.85 (s, 1H, H₁'), 7.9 (s, 1H, H₆), 9 (sl, 1H, NH),

N9-(3-deoxy-3-C-dihydroxyphosphono-β-D-ribofuranosyl)-adenine (ammonium salt) 23.

R_f = 0.3 (2-propanol / NH₄OH / H₂O, 7/1/2)

MS m/z (FAB < 0, G): 330 (anion)

RMN ³¹P (D₂O), δ: 14.66

RMN ¹H (D₂O), δ: 3.2 (ddd, 1H, H₃'), 4.5 (dd, 1H, H₅', J_{H₅'-H₅"}=12.3Hz and J_{H₄'-H₅'}=4.6Hz), 4.7 (dd, 1H, H₅"', J_{H₅"'-H₅"}=12.37Hz and J_{H₄'-H₅'}=3.5Hz), 5.3 (m, 1H, H₄'), 5.6 (m, 1H, H₂'), 6.8 (s, 1H, H₁'), 9 and 9.1 (2s, 2H, H₂ and H₈)

N9-(2,3-dideoxy-3-C-dihydroxyphosphono-β-D-ribofuranosyl)-adenine (ammonium salt) 24.

R_f = 0.3 (2-propanol / NH₄OH / H₂O, 7/1/2)

MS m/z (FAB < 0, G): 314 (anion)

RMN ³¹P (D₂O), δ: 17.66

RMN ¹H (D₂O), δ: 2-3 (3sl, 3H, H₂', H₂"' and H₃'), 3.7 (d, 1H, H₅', J_{H₅'-H₅"}=12.4), 3.9 (d, 1H, H₅"', J_{H₅"'-H₅"}=12.2Hz), 4.4 (m, 1H, H₄'), 6.3 (s, 1H, H₁'), 8.2 (s, 1H, H₈), 8.4 (s, 1H, H₂)

ACKNOWLEDGEMENTS: We would like to thank ANRS and "Fondation pour la recherche médicale" (section LR) for their generous support and Pr P. Scheiner for his helpful advices.

REFERENCES:

1. Engel R., *Chem. Rev.* **1977**, *77*, 349-366
2. Blackburn M. G. B. *Chem. Ind.* **1981**, 134-138
3. a. Parikh, J. R.; Wolff, M. E.; Burger A. *J. Am. Chem. Soc.* **1957**, *79*, 2778-2781; b. Bannister, B.; Kagan, F. *J. Am. Chem. Soc.* **1960**, *82*, 3363-3368; c. Yengoyan, L.; Rammler, D. H. *Biochemistry* **1966**, *5*, 3629-3638; d. Rammler, D. H.; Yengoyan, L. *Biochemistry* **1967**, *6*, 1828-1837; e. Holy, A. *Tetrahedron Lett* **1967**, *10*, 881-884; f. Albrecht, H. P.; Jones, G. H.; Moffatt, J. G. *J. Am. Chem. Soc.* **1970**, *92*, 5511-5513; g. Stock, J. A. *J. Org. Chem.* **1979**, *44*, 3997-3400; h. Albrecht, H. P.; Jones, G. H.; Moffatt, J. G. *Tetrahedron* **1984**, *40*, 79-85; i. Morr, M.; Ernst, L.; Kakoshke, C. G. *B. F. Monogr. Ser.* **1987**, *8*, 107-113; j. Walker, B. J.; Hobbs, J. B.; Allen, C. W.; Allen, D. W.; Dalh, O.; Edmundson, R. S.; Hall, C. D. *Organophosphorus Chemistry*, **1990**, *21*, 200-311
4. Engel, R. *Synthesis of carbon-phosphorus bonds* **1988**, Ed CRC Press and references cited therein
5. Paulsen, H.; Greve, W. *Chem. Ber.* **1973**, *106*, 2124-2139
6. Evelyn, L.; Hall, L. D.; Lynn, L.; Steiner, P. R.; Stokes, D. H. *Carbohydr. Res.* **1973**, *27*, 21-27
7. Dewynter, G-F.; Imbach, J-L.; Montero, J-L.; Serra, C. *French Patent* n°93 12557 **1993**
8. Bhat, C. C. "Synthetic Procedures in Nucleic Acid Chemistry", Zorbach W W, Tipson R S, eds Wiley Interscience, New York **1968**, *1*, 521
9. a. Mitsunobu, O. *Synthesis* **1981**, 1-28; b. Hughes, D. L. *Organic Reactions* **1992**, *42*, 335-657; c. Alfredsson, G.; Garegg, P. J. *Acta. Chem. Scand.* **1973**, *27*, 724-726
10. Gosselin, G.; Bergogne, M. C.; De Rudder, J.; De Clerq, E.; Imbach, J. L. *J. Med. Chem.* **1987**, *30*, 982-991
11. McEldoon, W.L.; Lee, K.; Wiemer, D.F. *Tetrahedron Lett.* **1993**, *34*, 5843-5846
12. Dolan, S. C.; Mac Milan, J. *J. Chem. Soc. Chem. Commun.* **1985**, 1588-1589
13. Mikhailopulo, I. A.; Sivets, G. G.; Pricota, T. I.; Poopeiko, N. E.; Balzarini, J.; De Clerq, E. *Nucleosides Nucleotides* **1991**, *10*, 1743-1757
14. Vordrüggen, H.; Bennua, B. *Tetrahedron Lett.* **1978**, 1339-1342
15. Génu-Dellac, C.; Gosselin, G.; Puech, F.; Henry, J. C.; Aubertin, A. M.; Obert, G.; Kim, A.; Imbach, J. L. *Nucleosides Nucleotides* **1991**, *10*, 1345-1376
16. Nakayama, C.; Saneyoshi, M., *Nucleosides Nucleotides* **1982**, *1*, 139-146
17. Saneyoshi, M.; Satoh, E. *Chem. Pharm. Bull.* **1979**, *27*, 2518-2521
18. Kakefuda, A.; Yoshimura, Y.; Sasaki, T.; Matsuda, A. *Tetrahedron* **1993**, *38*, 8513-8528
19. Schmidt, R. R.; Wegmann, B.; Jung, K. H. *Liebigs Ann. Chem.* **1991**, 121-124
20. Calvo-Mateo, A.; Camarasa, M. J.; Diaz-Ortiz, A.; De Las Heras, F. G. *Tetrahedron* **1988**, *44*, 4895-4903
21. Ishido, Y.; Nakasaki, N.; Sakairi, N. *J. Chem. Soc. Perkin I* **1979**, 2088-2097
22. Robins, M. J.; Wilson, J. J.; Hannske, F. *J. Am. Chem. Soc.* **1983**, *105*, 4059-4065
23. Seela, F.; Muth, H. P. *Liebigs Ann. Chem.* **1988**, 215-219
24. Lin, T. S.; Yang, J. H.; Gao, Y. S. *Nucleosides Nucleotides* **1990**, *9*, 97-108
25. Mikhailov, S. N.; Padyukova, N. S.; Karpeiskii, M. Y.; Kolobushkina, L. I.; Beigelman, L. N. *Collect. Czech. Chem. Commun.* **1989**, *54*, 1055-1066

(Received in Belgium 2 February 1994; accepted 19 April 1994)